- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05248477
Improve the Survival Without Morbidity of Extremely Preterm Infants (PREMEX) (PREMEX)
Improve the Survival Without Morbidity of Extremely Preterm Infants: A Stepped-wedge Cluster-randomized Trial
The intervention proposed is a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children. It will take place in each perinatal network for all pregnant women hospitalized between 22 and 26 weeks with a risk of preterm delivery.
Setting up the protocol requires taking into account the parents' time and timing issues, and its potential for change, to plan the implementation of the protocol, especially the degree of emergency of the situation and the probability of imminent delivery.
The follow-up collected for this study will take place:
- At D4 post-delivery: A questionnaire about the parents' experience of the information delivered and the decisions made will be given to and collected from the parents
At the child's discharge from the hospital, or if he or she dies in the hospital:
- Collection of clinical data (principal endpoint) from data in the medical file.
- Data to measure practices and adherence to the intervention will be collected
When the child reaches the corrected age of 2 years:
- a short questionnaire will be completed by the physician caring for the child at the corrected age of 2 years. The data collected will concern motor and sensory development, in particular, cerebral palsy, blindness, and deafness..
- Information about the child's development will also be collected with a questionnaire including a standardized assessment scale, the ASQ (Ages and Stages Questionnaire), which the parents will complete.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Extremely preterm infants, those born between 22 and 26 weeks of gestation, are at very high risk of neonatal death, severe morbidity, and disabilities. These children's survival basically depends on the obstetric-pediatric team's willingness to provide active care. In France, practices vary strongly according to the child's place of birth. The rates of active antenatal care (reflects the intention to manage the child actively at birth), standardized by gestational age, vary from 22% to 61% between regions. One of the consequences of this heterogeneity is that the survival rate in France of these extremely premature infants is much lower than that of countries offering similar levels of care. Among the children live-born in France, survival rates at hospital discharge were 0% at 22 weeks, 1% at 23, 31% at 24, 59% at 25, and 75% at 26 weeks. Survival in the USA, Great Britain, Japan, Australia, and Sweden ranges from 10 to 50% higher than in France.
The great variability of antenatal practices for the management of extremely preterm infants reflects the disarray of medical teams. In the absence of consensus and written decision-making processes, this uncertainty culminates in management decisions based at best on local habits and at worst on the individual habits of the clinician present. These habits vary with the physicians' beliefs or convictions, and their level of knowledge and experience of extremely preterm births. This variability of practices between hospitals presents a problem of equity.
The hypothesis is that standardization of the management of extremely preterm infants, from the moment that the pregnant woman is hospitalized until the child's birth should improve survival without severe morbidity in this group of children at very high risk
The intervention proposed is a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol (MC Lamau, et al, PMID: 34059380), involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children. It will take place in each perinatal network for all pregnant women hospitalized between 22 and 26 weeks with a risk of preterm delivery.
Setting up the protocol requires taking into account the parents' time and timing issues, and its potential for change, to plan the implementation of the protocol, especially the degree of emergency of the situation and the probability of imminent delivery.
Complex intervention, named the EXPRIM protocol, aimed at standardizing the organization of care. It is based on the following principles:
- A collective obstetric-pediatric prognostic assessment, in a non-emergency setting, no longer based only on gestational age, and ensuring better team consistency in terms of the attitude to propose to parents;
- A consensus decision by the multidisciplinary team about the obstetric and neonatal management proposed-either active or palliative care-at the conclusion of this prognostic evaluation
An interview with the parents to:
- inform them about the obstetric situation and the child's prognosis
- answer their questions
- propose either active or palliative care to them as management
- and then ask their opinion.
- The administration of corticosteroid therapy, independently of the decision about management (active or palliative care), starting at 23 weeks will be of broad indication;
If the hospitalization takes place in a level-1 or 2 hospital: after general information about preterm delivery, a proposal to transfer the woman to the perinatal network's level-3 hospital, starting at 23 weeks
The choice of a stepped-wedge cluster randomization design allows all perinatal networks to implement the intervention.
After the random drawing of clusters for the intervention, the teams will be trained in the EXPRIM protocol and then will undergo a 3-month transition period (not considered either a control or intervention period) to learn the protocol thoroughly. The data collected during this period will not be used in the analysis. In summary, the 3 stages before recruitment during the intervention are:
- allocation of clusters
- training of perinatal teams
- transition period After random drawing, 4 perinatal networks will be allocated to the intervention in 5 waves every 3 months, with 3 months of recruitment for the last wave. Twenty perinatal networks will be randomized and will participate in the trial with a total recruitment period of 21 months (including the 3-month transition periods). Overall, the duration of the study at each center will be 49 months. All perinatal networks will have a period with and without the intervention and will participate in the comparison accordingly. After 15 months all the networks will have begun the intervention.
No specific follow-up visit for the purposes of the study is planned. The hospital staff physicians will perform follow-up as part of the standard usual care for women and their newborns.
The follow-up collected for this study will take place:
- At D4 post-delivery (or before, if the woman leaves the hospital before then): A questionnaire about the parents' experience of the information delivered and the decisions made (see section 4.2) will be given to and collected from the parents
At the child's discharge from the hospital, or if he or she dies in the hospital:
- Collection of clinical data (principal endpoint) from data in the medical file. If the patient was transferred to another hospital, the PREMEX investigator and/or the CRT will obtain the follow-up data to enter on the e-CRF.
- Data to measure practices and adherence to the intervention will be collected
- The neonatologist-investigator will ask the parents at the child's discharge from hospitalization for written consent to continue their participation in this study for the follow-up at age 2.
When the child reaches the corrected age of 2 years:
- Nearly all the surviving children will be receiving care within structured networks for the follow-up of vulnerable children, responsible for "detailded description"optimizing their medical care and follow-up. Accordingly, a short questionnaire will be completed by the physician caring for the child at the corrected age of 2 years. The data collected will concern motor and sensory development, in particular, cerebral palsy, blindness, and deafness. The questionnaire will be sent to the parents, who will ask the physician to complete it at the medical visit planned at this age. The parents may be contacted by email or telephone if necessary. The physician will send the completed questionnaire to the project coordinators.
- Information about the child's development will also be collected with a questionnaire including a standardized assessment scale, the ASQ (Ages and Stages Questionnaire), which the parents will complete. The ASQ will be sent to them by either the postal service or email, together with the questionnaire to transmit to the physician. A telephone call will be made if necessary to recover the questionnaire data and remind the parents who have not responded. Once the parents have completed the questionnaire, they will send it to the project coordinating team.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- Recruiting
- Hôpital Cochin
-
Contact:
- Pierre-Henri JARREAU, MD, PhD
- Phone Number: +33 1 58 41 36 05
- Email: pierre-henri.jarreau@cch.aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
all newborns (live- and stillborn) delivered between 22 and 26 weeks
Exclusion Criteria
any fetus or child with a severe congenital anomaly (from the EPIPAGE-2 list)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: usual practice
|
|
EXPERIMENTAL: Premex protocol
a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children
|
This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival at hospital discharge without severe morbidity (composite outcome)
Time Frame: Up to 24 Weeks
|
Severe morbidity is a composite criterion assessed up to 40 post-menstrual age (PMA) and defined by at least one of the following severe neonatal morbidities:
|
Up to 24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child's survival at hospital discharge
Time Frame: Up to 24 Weeks
|
Number of living children
|
Up to 24 Weeks
|
Neurosensory condition ( composite outcome)
Time Frame: at a corrected age of 2 years.
|
Neurosensory condition, assessed by the pediatrician responsible for monitoring the child
|
at a corrected age of 2 years.
|
child's global development
Time Frame: at a corrected age of 2 years.
|
Assessment of the child's global development will be based on a standardized parent-completed questionnaire: the Ages and Stages Questionnaire (ASQ).
It allows the assessment of 5 major domains of child development (communication, gross motor skills, fine motor skills, problem resolution, and social relations).
When the score on one of these five dimensions is lower than 2 standard deviations below the norm, children are considered to be at risk of developmental disorders
|
at a corrected age of 2 years.
|
Medical economics:
Time Frame: at a corrected age of 2 years
|
Incremental cost-effectiveness ratio (ICER) defined by the ratio of the cost difference from the hospital's oint of view to the difference in survival, both overall and without severe morbidity; budgetary impact, assuming the widespread dissemination of these practices throughout France.
|
at a corrected age of 2 years
|
Parents' experience of the information they received, their involvement in decision making, and the decisions made
Time Frame: on day 4
|
This experience will be assessed by 2 simple questions to obtain responses on a scale ranging from 0 ("No, not at all") to 10 ("Yes, agree completely").
These 2 questions will concern their satisfaction, first with the care of the pregnancy and the child, and then with their participation or degree of involvement in decisions.
|
on day 4
|
Collaborators and Investigators
Investigators
- Study Director: Pierre-Henri JARREAU, MD, PhD, Assistance Publique - Hôpitaux de Paris
- Study Chair: Pierre-Yves ANCEL, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP211004
- 2021-A02520-41 (OTHER: ID-RCB Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborn
-
Inonu UniversityCompletedNewborn | Newborn Sleep | Newborn StressTurkey
-
Universidad Autonoma de Nuevo LeonCompletedHospital Readmission | Newborn Morbidity | Newborn | Newborn Complication
-
Assumpta Solome NantumeDLR German Aerospace Center; Academic Model Providing Access to Healthcare...RecruitingNewborn Morbidity | Newborn ComplicationKenya
-
Basaksehir Cam & Sakura Şehir HospitalCompletedNewborn Cardiac Surgery | Newborn HemostasisTurkey
-
Centre Hospitalier René DubosCompleted
-
Children's National Research InstitutePatient-Centered Outcomes Research InstituteCompletedPremature Birth of Newborn | Newborn Morbidity | Family | Immature Newborn | Infant Newborn DiseaseUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)Not yet recruitingNewbornUnited States
-
Istanbul University - Cerrahpasa (IUC)Completed
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
Clinical Trials on Premex Protocol
-
Hospices Civils de LyonRecruitingHealthy | Visual ImpairmentFrance
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedAutonomic Nervous System | Cardiorespiratory Parameters
-
Universidade Federal de Sao CarlosRecruiting
-
Saptadi YuliartoRecruiting
-
Véronique FlamandCHU de Quebec-Universite Laval; Centre Interdisciplinaire de Recherche en Réadaptation...UnknownDupuytren ContractureCanada
-
Instituto Docusse de Osteopatia e Terapia ManualCompleted
-
Thais Amanda RodriguesCompleted
-
Central Hospital, Nancy, FranceUnknownCruciate Ligament Injury | Balance ControlFrance
-
Loma Linda UniversityCompletedHemiplegia and/or Hemiparesis Following StrokeUnited States
-
UNICEF - VenezuelaRecruitingWasting | Acute Malnutrition in Childhood | Child MalnutritionVenezuela